The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem

blonca9
Oct 25, 2023
1 min read

Updated: Oct 26, 2023

Jeff Keyser tells us about trying to help patients recover from surgeries more efficiently and the phase 2 data that led to Renibus' breakthrough therapy designation.

Brought to you by:

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight